Áttétes emlőrák: vizsgálatok itt: Olaszország
70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking people18F-FES PET/MRI for tailoring treatment of luminal A and lobular breast cancer: a phase II trial evaluating the performance of FES PET/MRI in axillary staging
- Where
- Milan
- Életkor
- 18 év and over
- People
- 221
- Run by
- Universita' Vita-salute S. Raffaele
See details and how to joinNCT05982496 · EU 2024-512465-14-00 - No phaseTaking peopleAnalysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer
- Where
- Milan
- Életkor
- 18 év and over
- People
- 30
- Run by
- European Institute of Oncology
See details and how to joinNCT06706557 - No phaseTaking peoplePIK3CA Mutational Status Assessment
- Where
- Milan
- Életkor
- 18 év and over
- People
- 100
- Run by
- European Institute of Oncology
See details and how to joinNCT06706570 - No phaseTaking peopleIntegrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,
- Where
- Milan
- Életkor
- 18 év and over
- People
- 80
- Run by
- European Institute of Oncology
See details and how to joinNCT06762483 - 4. fázisTaking peopleIMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)
- Where
- Florence, Prato
- Életkor
- 65 év and over
- People
- 495 worldwide
- Run by
- Region Oerebro Laen
See details and how to join2023-506620-87-00 - 3. fázisTaking peopleFDG-PET/CT vs. CT for Monitoring Metastatic Breast Cancer
- Where
- Bologna, Candiolo, Rozzano
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT06877949 · EU 2023-508591-11-00 - No phaseTaking peopleToxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast Cancer
- Where
- Milan
- Életkor
- 18 év and over
- People
- 84
- Run by
- European Institute of Oncology
See details and how to joinNCT07049133 - 2. fázisTaking peopleAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
- Where
- Brindisi, Milan, Monza, Roma
- Életkor
- 18 év and over
- People
- 45
- Run by
- European Institute of Oncology
See details and how to joinNCT06690840 - 2. fázisTaking peopleThe combination of Elacestrant and exemestane for patients with pretreated metastatic breast cancer expressing hormone receptors and non-expressing HER2, with lesions which uptake [18F]FES-avid (COMBINE): a proof-of-concept phase 2 clinical trial
- Where
- Milan
- Életkor
- 18 év and over
- People
- 26
- Run by
- Istituto Europeo Di Oncologia S.r.l.
See details and how to join2024-519792-25-00 - 1. fázisTaking peopleFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Where
- Milan
- Életkor
- 18 év and over
- People
- 930 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT05216432 - 2. fázisFut, nem toborozRestoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
- Where
- Bergamo, Milan, Napoli, Novara, Padova, Reggio Emilia
- Életkor
- 18 év and over
- People
- 37
- Run by
- IFOM ETS - The AIRC Institute of Molecular Oncology
See details and how to joinNCT05582538 · EU 2024-513721-23-00 - 2. fázisTaking peopleA phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer
- Where
- Meldola, Modena, Parma, Reggio Emilia
- Életkor
- 18 év and over
- People
- 53
- Run by
- Azienda Ospedaliero Universitaria Di Modena
See details and how to join2024-515686-34-00 - No phaseTaking peopleRADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
- Where
- Milan
- People
- 500
- Run by
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
See details and how to joinNCT07030569 - No phaseTaking peopleConcomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
- Where
- Rome
- Életkor
- 18 év and over
- People
- 300
- Run by
- Fondazione Policlinico Universitario Campus Bio-Medico
See details and how to joinNCT07021911 - No phaseTaking peopleWhole Body MRI in Oncology
- Where
- Bologna, Meldola, Milan
- Életkor
- 18 év and over
- People
- 1000
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06895291 - No phaseTaking peoplePredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
- Where
- Aviano, Brescia, Catania, Como, Cremona, Florence, Genova, Meldola, Milan, Mirano, Modena, Naples, Novara, Padova, Pavia, Roma, Rozzano
- Életkor
- 18 év and over
- People
- 3500
- Run by
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
See details and how to joinNCT06805812 - No phaseTaking peopleEvaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers
- Where
- Bologna
- Életkor
- 18 év and over
- People
- 100
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT06800612 - No phaseTaking peopleIncreasing Oral Medication Adherence for Metastatic Breast Cancer Patients
- Where
- Milan
- Életkor
- 18 év and over
- People
- 104
- Run by
- European Institute of Oncology
See details and how to joinNCT06726889 - 3. fázisNot yet taking people in OlaszországImplementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
- Where
- Florence, Prato
- Életkor
- 70 év and over
- People
- 495 worldwide
- Run by
- Region Örebro County
See details and how to joinNCT06044623 - 2. fázisTaking peopleClinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP
- Where
- Milan
- Életkor
- 18 év and over
- People
- 400
- Run by
- Istituto Europeo Di Oncologia S.r.l.
See details and how to join2024-513934-40-00